LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly (LLY) has won Health Canada approval for Omvoh (mirikizumab) in patients with Crohn’s disease, the company said on ...

Eli Lilly Canada Inc. (Lilly Canada) announced today that Health Canada has approved Omvoh® (mirikizumab) for CD, which will soon be available to patients in Canada. Omvoh® is an interleukin-23p19 ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

The National Institute for Health and Care Excellence (NICE) has published final guidance recommending Eli Lilly’s Omvoh ...

Health technology assessment (HTA) agency NICE has published final draft guidance for IL-23 inhibitor Omvoh (mirikizumab), ...

Eli Lilly’s blockbuster GLP-1 drugs dominate headlines, but its broader portfolio deserves a standing ovation for driving ...

Some key growth products include the oncology drug Verzenio and immunology drug Taltz, which accounted for 9% and 6% of total ...

Lilly Pulitzer's Crazy Summer Sale Has Finds Starting at Just $5: Shop Dresses, Swimwear and More This is the time to save big at Lilly Pulitzer.

Evangeline Lilly has cancelled an appearance at the Italian Global Series Festival as she recuperates from a recent fall.

Eli Lilly and Company’s (LLY) shares dropped 6.6% following the release of disappointing fourth-quarter sales and a reduced revenue outlook for 2024. The company’s revenues for Q4 fell short due to ...